Found "Pharmaceuticals": 23 results
Indoor Air Pollution of Volatile Organic Compounds (VOCs) in Hospitals in Thailand: Review of Current Practices, Challenges, and Recommendations
Indoor air pollution has become a significant concern, contributing to the decline in air quality through the presence of gaseous pollutants and particulate matter, especially under poor ventilation. Hospitals, functioning as non-industrial microenvironments, particularly in Thailand, face challenge
Indoor Air Pollution of Volatile Organic Compounds (VOCs) in Hospitals in Thailand: Review of Current Practices, Challenges, and Recommendations
Indoor air pollution has become a significant concern, contributing to the decline in air quality through the presence of gaseous pollutants and particulate matter, especially under poor ventilation. Hospitals, functioning as non-industrial microenvironments, particularly in Thailand, face challenges due to insufficient and incomplete databases for
Designing a decision frame for making health resource allocation decisions: a case study in Thailand
The abundance of various innovations in healthcare (pharmaceuticals, medical devices, interventions, individual and community health promotion and disease prevention as well as a social health policy) have been continuously used in the healthcare system, resulting in a higher demand for resources and budgets in disease prevention and healthcare. Th
Development of health technology assessment management
The Health Intervention and Technology Assessment Program (HITAP) was established in 2007 as a non-profit organization. Its main responsibility is to assess health interventions and technology assessment with the coverage of pharmaceuticals, medical devices, interventions, individual and community health promotions and disease prevention, as well a
A Determination of Topics for Health Technology Assessment in Thailand: Case Study for Decision Makers Participation (2007-2008) (in Thai language)
An aim of this study is to describe quantitatively and qualitatively progression and findings from the HTA topic selection process recently developed by HITAP. The process involves potential users of HTA information; namely (1) third party payers (public health insurers), (2) national health care program managers (Ministry of Public Health’s Depa
Assessing the implications of Thailand’s government use licenses, issued in 2006-2008
This study aims to assess the impact of the compulsory licensing (CL ) policy issued by Thailand’s Ministry of Public Health during December 2006 to January 2008 on antiretroviral drugs - efavirenz and lopinavir/ritonavir combination, an oral antiplatelet agent - clopidogrel, and four anti-cancer drugs - imatinib, erlotinib, letrozole, and doceta
Health Technology Assessment Development in Bhutan
Bhutan\'s Ministry of Health, especially the Essential Medicine and Technology Division (EMTD), is one of HITAP\'s long-term partners. From 2018 to 2019, HITAP with PATH supported Bhutan to conduct an economic evaluation for the implementation of a national program for rotavirus vaccination. HITAP also provided and continues to find opportunities f
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients in the Thai healthcare system
The Thai healthcare system faces pressure to fund high-cost new branded pharmaceuticals. Paying more may encourage innovation with positive implications for future population health, but it also means less money is available to fund other healthcare with negative implications for current population health. Recent work in the UK estimated, for the f
Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. (2013)
Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand.
Inthira Yamabhai; Richard D. Smith
Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T
FDA approves Ironwood constipation drug
The drug, linaclotide, will be sold under the brand name Linzess and carry a boxed warning that it should not be used in patients 16 or younger, the agency said.An estimated 63 million people suffer from chronic constipation, according to the National Institutes of Health. Additionally, an estimated
10 / Page